Eisele G, Bailie G R, Clement C, Wong E
Albany College of Pharmacy, New York 12208.
Perit Dial Int. 1992;12(1):34-6.
Experience in the use of subcutaneous erythropoietin (EPO) in 32 continuous ambulatory peritoneal dialysis (CAPD) patients is presented. All patients were treated with oral iron supplements. The total and mean +/- SD durations of EPO treatment were 466 weeks and 14.6 +/- 10.1 weeks respectively. Twenty-two patients started treatment with normal or elevated iron stores; 10 had an initial iron saturation less than 20%. The initial hematocrit was 23.8 +/- 3.7%. Thirteen patients reached a steady-state hematocrit by the end of the study period, when the mean +/- SD hematocrit for all 32 patients was 34.1 +/- 3.6%. All patients responded to EPO. The initial dose of EPO was 147.1 +/- 53.8 U/kg/week. Maintenance dose was 72 +/- 36 U/kg/week.
本文介绍了32例持续性非卧床腹膜透析（CAPD）患者使用皮下促红细胞生成素（EPO）的经验。所有患者均接受口服铁剂补充治疗。EPO治疗的总时长和平均±标准差时长分别为466周和14.6±10.1周。22例患者开始治疗时铁储备正常或升高；10例患者初始铁饱和度低于20%。初始血细胞比容为23.8±3.7%。13例患者在研究期末达到稳定状态血细胞比容，此时所有32例患者的平均±标准差血细胞比容为34.1±3.6%。所有患者对EPO均有反应。EPO初始剂量为147.1±53.8 U/kg/周。维持剂量为72±36 U/kg/周。
